Alk Abello As Stock Earnings Reports

ALK reported a strong Q1: revenue grew ~18% (to ~DKK 1.8bn) and EBIT rose 22% with a Q1 EBIT margin of 32%. For the first time ALK’s quarterly tablet sales exceeded DKK 1bn, driven by double‑digit growth across regions (particularly Europe and Canada) and strong uptake of pediatric tablet indications. Gross margin improved to ~69% but is expected to normalize as partner‑related, lower‑margin revenue rises. Strategic highlights: positive Phase II ALLIANCE results for the peanut allergy tablet (dose‑dependent, statistically significant efficacy across ages, safe and well tolerated) and plans to initiate Phase III in late 2026; regulatory progress and early launches for EURneffy (needle‑free adrenaline) including EU 1 mg (children) and Canada 2 mg approvals; continued pediatric tablet rollouts and progress on other respiratory programs. Management upgraded FY26 guidance: revenue growth now expected at 13–16% (local currencies) and an EBIT margin around 26%, while continuing to invest in commercial rollout (pediatrics, neffy), R&D (including ALK‑014 anti‑IgE preclinical work) and AI. Key risks called out: potential pricing/rebate changes (notably German rebate discussions), increasing capacity costs (investments), and near‑term margin pressure from higher share of partner revenue and upcoming large clinical investments (peanut Phase III, possible ALK‑014 development). Cash generation was strong (positive free cash flow) and management reiterated disciplined capital allocation with organic investment first, selective BD/M&A, and shareholder returns once internal needs are met.